cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.
Company profile
Ticker
CVRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CVRX INC
SEC CIK
Corporate docs
Subsidiaries
CVRx Switzerland LLC ...
CVRX stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
CVRx Reports First Quarter 2024 Financial and Operating Results
30 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
11 Apr 24
S-8
Registration of securities for employees
9 Feb 24
S-8
Registration of securities for employees
9 Feb 24
10-K
2023 FY
Annual report
9 Feb 24
8-K
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
31 Jan 24
8-K
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25 Jan 24
Transcripts
CVRX
Earnings call transcript
2024 Q1
30 Apr 24
CVRX
Earnings call transcript
2023 Q4
25 Jan 24
CVRX
Earnings call transcript
2023 Q3
26 Oct 23
CVRX
Earnings call transcript
2023 Q2
25 Jul 23
CVRX
Earnings call transcript
2023 Q1
27 Apr 23
CVRX
Earnings call transcript
2022 Q4
26 Jan 23
CVRX
Earnings call transcript
2022 Q3
2 Nov 22
CVRX
Earnings call transcript
2022 Q2
29 Jul 22
CVRX
Earnings call transcript
2022 Q1
25 Apr 22
CVRX
Earnings call transcript
2021 Q4
16 Feb 22
Latest ownership filings
4
Craig E. Palmer
27 Mar 24
4
& JOHNSON JOHNSON
6 Mar 24
4
PAUL VERRASTRO
27 Feb 24
4
PAUL VERRASTRO
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
4
Kevin Hykes
14 Feb 24
SC 13G/A
Vensana Capital I GP, LLC
6 Feb 24
4
Craig E. Palmer
6 Feb 24
4
JARED OASHEIM
6 Feb 24
4
PAUL VERRASTRO
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm |
Cash burn (monthly) | 2.61 mm | 2.25 mm | 3.18 mm | 3.74 mm | 2.71 mm | 3.50 mm |
Cash used (since last report) | 19.21 mm | 16.57 mm | 23.40 mm | 27.58 mm | 19.95 mm | 25.80 mm |
Cash remaining | 63.78 mm | 66.42 mm | 59.59 mm | 55.41 mm | 63.04 mm | 57.19 mm |
Runway (months of cash) | 24.5 | 29.5 | 18.8 | 14.8 | 23.3 | 16.3 |
Institutional ownership, Q4 2023
31.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 64 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 4.85 bn |
Total shares | 6.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 10 L P | 2.20 mm | $56.00 mm |
Vensana Capital I GP | 1.71 mm | $0.00 |
Cooperatieve Gilde Healthcare IV U.A. | 1.60 mm | $49.16 mm |
Soleus Capital Master Fund | 1.01 mm | $0.00 |
GSG Advisors | 160.51 k | $4.74 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 151 | 35.79 | 1,229 |
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 404 | 95.75 | 1,078 |
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 379 | 89.82 | 674 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 151 | 35.79 | 0 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 404 | 95.75 | 0 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 379 | 89.82 | 0 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 5.141 | 79 | 406.14 | 4,103,430 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 3.955 | 252 | 996.66 | 4,103,351 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 142 | 168.41 | 4,103,099 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 442 | 524.21 | 4,102,957 |
News
Lake Street Maintains Buy on CVRx, Lowers Price Target to $18
1 May 24
Canaccord Genuity Maintains Buy on CVRx, Lowers Price Target to $14
1 May 24
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates
1 May 24
Craig-Hallum Assumes CVRx at Buy, Lowers Price Target of $23
1 May 24
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
1 May 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX
6 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX
2 May 24
Investigation Into CVRx, Inc. (CVRX) Announced by Holzer & Holzer, LLC
1 May 24
Stay Informed: Johnson Fistel, LLP Investigates CVRx - Investor News
1 May 24
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
16 Apr 24